Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone

被引:11
|
作者
Palomba, S [1 ]
Morelli, M [1 ]
Di Carlo, C [1 ]
Noia, R [1 ]
Pellicano, M [1 ]
Zullo, F [1 ]
机构
[1] Univ Catanzaro, Dept Obstet & Gynecol, Chair Obstet & Gynecol, Catanzaro, Italy
关键词
GnRH-a; tibolone; bone loss; BMD; postmenopause; analog; leiomyoma;
D O I
10.1016/S0015-0282(02)03149-7
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To study the bone metabolism in postmenopausal women who have been treated with gonadotropin-releasing hormone agonist (GnRH-a) and tibolone. Design: Prospective, open. controlled clinical trial. Setting: Department of Gynecology and Obstetrics, University of Catanzaro, Catanzaro, Italy. Patient(s): One hundred twenty perimenopausal women with symptomatic uterine leiomyomas (groups A and 13), and 40 healthy control women who underwent a normal spontaneous menopause (group C). Intervention(s): Treatment for 12 months with leuprolide acetate plus tibolone (group A) or hysterectomy with bilateral oophorectomy (group B). Main Outcome Measure(s): Lumbar spine bone mineral density (BMD) and bone turnover markers at entry into the study, after medical treatment (only group A), and 12 months after discontinuation medical treatment (group A) or after surgery (group 13). The same parameters were noted in healthy women before and 12 months after menopause (retrospective control group, group C). Result(s): At the women's entry into the study, no significant difference in BMD and bone turnover markers was detected between groups A and B. In group A. no significant variation in BMD or bone turnover markers was observed 12 months after medical treatment in comparison with baseline. At 12 months after discontinuation of treatment (in women who had achieved menopause) and after surgery, we observed a statistically significant decrease in BMD and in bone turnover markers in both groups in comparison with baseline. At 12 months after they became menopausal, we also observed a statistically significant reduction in BMD and in bone turnover markers in control group C. At the same 12-month follow-up visit, a statistically significant difference in BMD and in bone turnover markers was detected when comparing groups A and B with group C. Conclusion(s): Women previously treated with GnRH-a and tibolone similar to women who are menopausal as a result of surgery, have higher bone loss after menopause. (C) 2002 by American Society for Reproductive Medicine.
引用
收藏
页码:63 / 68
页数:6
相关论文
共 50 条
  • [1] Depression in women treated with a gonadotropin-releasing hormone agonist
    Toren, P
    Dor, J
    Mester, R
    Mozes, T
    Blumensohn, R
    Rehavi, M
    Weizman, A
    [J]. BIOLOGICAL PSYCHIATRY, 1996, 39 (05) : 378 - 382
  • [2] Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: Effects on bone metabolism
    Palomba, S
    Orio, F
    Morelli, M
    Russo, T
    Pellicano, M
    Nappi, C
    Mastrantonio, P
    Lombardi, G
    Colao, A
    Zullo, F
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (10): : 4476 - 4481
  • [3] THE EFFECT OF A GONADOTROPIN-RELEASING HORMONE AGONIST ANALOG (NAFARELIN) ON BONE METABOLISM
    JOHANSEN, JS
    RIIS, BJ
    HASSAGER, C
    MOEN, M
    JACOBSON, J
    CHRISTIANSEN, C
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 67 (04): : 701 - 706
  • [4] Gonadotropin-Releasing Hormone Agonist Treatment in Postmenopausal Women with Hyperandrogenism of Ovarian Origin
    Vollaard, Esther S.
    van Beek, Andre P.
    Verburg, Frederik A. J.
    Roos, Annemieke
    Land, Jolande A.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (05): : 1197 - 1201
  • [5] Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist
    Moghetti, P
    Castello, R
    Zamberlan, N
    Rossini, M
    Gatti, D
    Negri, C
    Tosi, F
    Muggeo, M
    Adami, S
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (04): : 1250 - 1254
  • [6] ABSORPTION AND METABOLISM OF NAFARELIN, A POTENT AGONIST OF GONADOTROPIN-RELEASING HORMONE
    CHAN, RL
    HENZL, MR
    LEPAGE, ME
    LAFARGUE, J
    NERENBERG, CA
    ANIK, S
    CHAPLIN, MD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (03) : 275 - 282
  • [7] Comment on spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist
    Prezelj, J
    Kocijancic, A
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (12): : 4747 - 4747
  • [8] Negative regulation of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor gene expression by a gonadotropin-releasing hormone agonist in the rat hypothalamus
    Han, YG
    Kang, SS
    Seong, JY
    Geum, D
    Suh, YH
    Kim, K
    [J]. JOURNAL OF NEUROENDOCRINOLOGY, 1999, 11 (03) : 195 - 201
  • [9] The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl)
    Lindsay, PC
    Shaw, RW
    Bennink, HJC
    Kicovic, P
    [J]. FERTILITY AND STERILITY, 1996, 65 (02) : 342 - 348
  • [10] CONVERSION OF A GONADOTROPIN-RELEASING HORMONE ANTAGONIST TO AN AGONIST
    CONN, PM
    ROGERS, DC
    STEWART, JM
    NIEDEL, J
    SHEFFIELD, T
    [J]. NATURE, 1982, 296 (5858) : 653 - 655